Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Futura Medical ( (GB:FUM) ) has shared an announcement.
Futura Medical has announced the dispatch of a Circular and Notice of General Meeting to shareholders, following a recent fundraise of £2.75 million. The meeting is scheduled for December 2, 2025, at the company’s registered office in Surrey. This development is part of Futura’s ongoing efforts to strengthen its financial position and enhance its market presence in the sexual health industry, potentially impacting stakeholders positively by addressing unmet needs in the market.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative and clinically proven sexual health products. Their core strength lies in topically delivered gel formulations, with products like Eroxon® for Erectile Dysfunction and WSD4000 for women’s sexual dysfunction. The company has distribution partners in major markets, including the US and Europe.
Average Trading Volume: 2,041,135
Technical Sentiment Signal: Sell
Current Market Cap: £6.73M
For an in-depth examination of FUM stock, go to TipRanks’ Overview page.